Paliperidone Extended-Release for the Treatment of Schizophrenia

Paliperidone, the major active metabolite of risperidone (9‐hydroxy‐risperidone), is a second‐generation antipsychotic that was recently approved by the United States Food and Drug Administration for treatment of acute schizophrenia and for maintenance treatment of schizophrenia. We performed a lite...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 2008-10, Vol.28 (10), p.1283-1298
Main Authors: Marino, Jehan, Caballero, Joshua
Format: Article
Language:English
Subjects:
9-OH risperidone
acute
Acute Disease
Adult and adolescent clinical studies
Antipsychotic Agents - adverse effects
Antipsychotic Agents - pharmacology
Antipsychotic Agents - therapeutic use
Biological and medical sciences
cost
Delayed-Action Preparations
Drug Interactions
extended-release tablets
Fees, Pharmaceutical
Humans
Isoxazoles - adverse effects
Isoxazoles - pharmacology
Isoxazoles - therapeutic use
maintenance
Medical sciences
paliperidone
Paliperidone Palmitate
Pharmacology. Drug treatments
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychoses
Pyrimidines - adverse effects
Pyrimidines - pharmacology
Pyrimidines - therapeutic use
safety
Schizophrenia
Schizophrenia - drug therapy
tolerability
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Paliperidone, the major active metabolite of risperidone (9‐hydroxy‐risperidone), is a second‐generation antipsychotic that was recently approved by the United States Food and Drug Administration for treatment of acute schizophrenia and for maintenance treatment of schizophrenia. We performed a literature search of PreMEDLINE, MEDLINE, and International Pharmaceutical s from 1966‐October 2007 to review the available data on the pharmacology, pharmacokinetics, clinical evidence, and safety and tolerability profile of paliperidone extended‐release (ER). Articles from randomized controlled trials, s, and posters presented at national scientific meetings were included in this review. Paliperidone ER has been shown to be significantly more effective in improving schizophrenic symptoms according to the Positive and Negative Symptom Scale (PANSS), Clinical Global Impressions‐Severity Scale, and Personal and Social Performance Scale compared with placebo (p
ISSN:0277-0008
1875-9114
DOI:10.1592/phco.28.10.1283